BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21480314)

  • 1. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus.
    Peng ZG; Zhao ZY; Li YP; Wang YP; Hao LH; Fan B; Li YH; Wang YM; Shan YQ; Han YX; Zhu YP; Li JR; You XF; Li ZR; Jiang JD
    Hepatology; 2011 Apr; 53(4):1080-9. PubMed ID: 21480314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host APOBEC3G protein inhibits HCV replication through direct binding at NS3.
    Zhu YP; Peng ZG; Wu ZY; Li JR; Huang MH; Si SY; Jiang JD
    PLoS One; 2015; 10(3):e0121608. PubMed ID: 25811715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G.
    Cen S; Peng ZG; Li XY; Li ZR; Ma J; Wang YM; Fan B; You XF; Wang YP; Liu F; Shao RG; Zhao LX; Yu L; Jiang JD
    J Biol Chem; 2010 May; 285(22):16546-52. PubMed ID: 20363737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human-APOBEC3G-dependent restriction of porcine endogenous retrovirus replication is mediated by cytidine deamination and inhibition of DNA strand transfer during reverse transcription.
    Jin SY; Choi HY; Kim HS; Jung YT
    Arch Virol; 2018 Jul; 163(7):1907-1914. PubMed ID: 29610985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
    Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
    Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity.
    Wang H; Zhong M; Li Y; Li K; Wu S; Guo T; Cen S; Jiang J; Li Z; Li Y
    Antiviral Res; 2019 May; 165():23-33. PubMed ID: 30862444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional analysis of the two cytidine deaminase domains in APOBEC3G.
    Li X; Ma J; Zhang Q; Zhou J; Yin X; Zhai C; You X; Yu L; Guo F; Zhao L; Li Z; Zeng Y; Cen S
    Virology; 2011 Jun; 414(2):130-6. PubMed ID: 21489586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like cytidine deaminase expression, hepatitis B virus (HBV) replication and HBV-associated liver disease (Review).
    He X; Li J; Wu J; Zhang M; Gao P
    Mol Med Rep; 2015 Nov; 12(5):6405-14. PubMed ID: 26398702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding.
    Bennett RP; Presnyak V; Wedekind JE; Smith HC
    J Biol Chem; 2008 Mar; 283(12):7320-7. PubMed ID: 18165230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.
    Zhang L; Saadatmand J; Li X; Guo F; Niu M; Jiang J; Kleiman L; Cen S
    Virology; 2008 Jan; 370(1):113-21. PubMed ID: 17916373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.
    Ulenga NK; Sarr AD; Hamel D; Sankale JL; Mboup S; Kanki PJ
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1285-90. PubMed ID: 18851679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.
    Armitage AE; Deforche K; Chang CH; Wee E; Kramer B; Welch JJ; Gerstoft J; Fugger L; McMichael A; Rambaut A; Iversen AK
    PLoS Genet; 2012; 8(3):e1002550. PubMed ID: 22457633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein.
    Pan T; He X; Chen B; Chen H; Geng G; Luo H; Zhang H; Bai C
    Eur J Med Chem; 2015 May; 95():500-13. PubMed ID: 25847768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation.
    Ma L; Zhang Z; Liu Z; Pan Q; Wang J; Li X; Guo F; Liang C; Hu L; Zhou J; Cen S
    Sci Rep; 2018 May; 8(1):8067. PubMed ID: 29795228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals.
    Biasin M; Piacentini L; Lo Caputo S; Kanari Y; Magri G; Trabattoni D; Naddeo V; Lopalco L; Clivio A; Cesana E; Fasano F; Bergamaschi C; Mazzotta F; Miyazawa M; Clerici M
    J Infect Dis; 2007 Apr; 195(7):960-4. PubMed ID: 17330785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.
    Derse D; Hill SA; Princler G; Lloyd P; Heidecker G
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2915-20. PubMed ID: 17299050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in the study of HIV-1 Vif and related inhibitors].
    Li ZY; Zhan P; Liu XY
    Yao Xue Xue Bao; 2010 Jun; 45(6):684-93. PubMed ID: 20939174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
    Franca R; Spadari S; Maga G
    Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.